CSIMarket
 
Clearmind Medicine Inc  (NASDAQ: CMND)
 
Price: $1.7778 $-0.16 -8.361%
Day's High: $1.9299999475479126 Week Perf: 3.36 %
Day's Low: $ 1.76 30 Day Perf: 9.07 %
Volume (M): 180,491 52 Wk High: $ 524.00
Volume (M$): $ 0 52 Wk Avg: $90.63
Open: $1.93 52 Wk Low: $1.43



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 0
 Employees 1
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -12
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


We were incorporated in the State of Delaware on May 28, 2014 and are a development stage company. Our company is developing an online service www.caleminder.net that provides a calendar- based greeting and reminder service to assist subscribers in remembering important life events such as birthdays, anniversaries, etc.

Users will register with the system and enter these important dates as well as configure a variety of settings, including when they want to be notified, for example one month prior, two weeks prior, one week prior, etc. Currently the application is web based and not for a mobile download application.



   Company Address: 101 – 1220 West 6th Avenue Vancouver 0
   Company Phone Number: 536.1016   Stock Exchange / Ticker: NASDAQ CMND


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALZN        3.52% 
ANRO   -2.42%    
CMPS   -10.75%    
ENVB   -6.16%    
INDV   -2.09%    
KTTA        1.71% 
• View Complete Report
   



Announcement

Clearmind Medicine Unwavering Progress in the Quest for Alcohol Use Disorder Treatments Amidst Financial Challenges

Published Mon, Nov 24 2025 5:02 PM UTC

In a noteworthy development within the biotech landscape, Clearmind Medicine Inc. (Nasdaq: CMND), a Vancouver-based company dedicated to pioneering novel therapeutics for under-treated health issues, has received unanimous endorsement from its independent Data and Safety Monitoring Board (DSMB) to continue its Phase I/IIa clinical trial for CMND-100. This proprietary neuropl...

Announcement

Clearmind Medicine Pioneers AUD Treatment Expansion Innovative Trials Surge Ahead Despite Market Fluctuati...

Published Thu, Nov 13 2025 2:00 PM UTC

In a significant advancement for the future of Alcohol Use Disorder (AUD) treatment, Clearmind Medicine Inc. (Nasdaq: CMND, FSE: CWY0) announced it has received final approval to expand its innovative Phase 1/2a clinical trial at the prestigious Hadassah Medical Center in Jerusalem, Israel. The company, known for pioneering psychedelic-derived therapeutics to address under-t...

Announcement

Clearmind Medicine Receives Patent Approval Amidst Market Challenges

Published Thu, Apr 17 2025 12:40 PM UTC

In a significant development for the biotechnology sector, Clearmind Medicine Inc. (NASDAQ: CMND) has received a notice of allowance for a patent covering its innovative approach to mitigating binge behavior, contributing to its arsenal in the fight against alcohol use disorder (AUD). As of the time of writing, Clearmind s shares are trading at $0.92, marking a noteworthy mo...

Clinical Study

Clearmind Medicine Leading the Psychedelic Therapeutics Revolution for AUD and Obesity,

Published Fri, Mar 21 2025 4:38 PM UTC

Clearmind Medicine: Pioneering Psychedelic-Derived Therapeutics for Alcohol Use Disorder and Obesity In the rapidly evolving field of pharmaceutical development, Clearmind Medicine Inc. is standing out as a trailblazer with its focus on psychedelic-derived therapeutics. At the forefront of this Vancouver-based biotech company’s endeavors is their innovative drug candidate,...

Announcement

Clearmind Medicine Inc. Navigates Financial Strains with Innovative Intranasal Psychedelic Therapies,

Published Wed, Mar 19 2025 12:27 PM UTC

In an ambitious move to enhance the effectiveness of its psychedelic-based treatments, Clearmind Medicine Inc. has announced plans to evaluate the intranasal delivery of its unique psychedelic drug combinations. This strategic initiative is aimed at improving the bioavailability and optimizing the therapeutic effects of their groundbreaking treatments. As the company embarks...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 0.03
PEG (TTM) -

Financial Strength Current
Quick Ratio -
Working Capital Ratio -
Leverage Ratio (MRQ) 0.35
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -463.1 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash 58.77 $
Book Value 52.3 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -12,475,420
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.